U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H28N2O.C6H8O7
Molecular Weight 528.5951
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FENTANYL CITRATE

SMILES

CCC(=O)N(c1ccccc1)C2CCN(CCc3ccccc3)CC2.C(C(=O)O)C(CC(=O)O)(C(=O)O)O

InChI

InChIKey=IVLVTNPOHDFFCJ-UHFFFAOYSA-N
InChI=1S/C22H28N2O.C6H8O7/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-12,21H,2,13-18H2,1H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

HIDE SMILES / InChI

Molecular Formula C22H28N2O
Molecular Weight 336.4713
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C6H8O7
Molecular Weight 192.1238
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.addictioncenter.com/painkillers/fentanyl/ | https://www.ncbi.nlm.nih.gov/pubmed/24635521

Fentanyl is a potent agonist of mu opioid receptor. It is used to relieve severe pain, such as after surgery or during cancer treatment, and breakthrough pain (flare-ups of intense pain despite round-the-clock narcotic treatment). Fentanyl is an extremely powerful analgesic, 50–100-times more potent than morphine. Fentanyl harbors massive risk for addiction and abuse regardless of its prescription form. Fentanyl abuse is especially dangerous to those without a tolerance to opioids. The substance’s already elevated risk of overdose is multiplied when someone without a tolerance abuses it.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.15 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DURAGESIC-100

Approved Use

Fentanyl transdermal system is a transdermal formulation of fentanyl indicated for the management of persistent, moderate to severe chronic pain in opioid-tolerant patients 2 years of age and older when a continuous, around-the-clock opioid analgesic is required for an extended period of time, and the patient cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids. Patients considered opioid-tolerant are those who are taking at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid for a week or longer. Fentanyl transdermal system contains fentanyl, a full opioid agonist. Fentanyl transdermal system is indicated for the management of persistent, moderate to severe chronic pain in opioid‑tolerant patients 2 years of age and older when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. (1) Fentanyl transdermal system is NOT intended for use as an as-needed analgesic. (1)

Launch Date

6.4998723E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.91 ng/mL
100 μg single, intravenous
dose: 100 μg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FENTANYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.61 ng/mL
400 μg single, oral transmucosal
dose: 400 μg
route of administration: Oral transmucosal
experiment type: SINGLE
co-administered:
FENTANYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.81 ng/mL
400 μg single, sublingual
dose: 400 μg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
FENTANYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.76 ng × h/mL
100 μg single, intravenous
dose: 100 μg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FENTANYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4.18 ng × h/mL
400 μg single, oral transmucosal
dose: 400 μg
route of administration: Oral transmucosal
experiment type: SINGLE
co-administered:
FENTANYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
5.76 ng × h/mL
400 μg single, sublingual
dose: 400 μg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
FENTANYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.5 h
100 μg single, intravenous
dose: 100 μg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FENTANYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7.9 h
400 μg single, oral transmucosal
dose: 400 μg
route of administration: Oral transmucosal
experiment type: SINGLE
co-administered:
FENTANYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
10 h
400 μg single, sublingual
dose: 400 μg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
FENTANYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
6 mg single, transdermal (total)
Overdose
Dose: 6 mg
Route: transdermal
Route: single
Dose: 6 mg
Sources: Page: p.463
healthy, 15
n = 1
Health Status: healthy
Age Group: 15
Sex: F
Population Size: 1
Sources: Page: p.463
Disc. AE: Apnea, Respiratory depression...
AEs leading to
discontinuation/dose reduction:
Apnea
Respiratory depression
Bradypnea
Tachycardia
Diaphoresis
Sources: Page: p.463
150 ug 1 times / hour multiple, transdermal
Overdose
Dose: 150 ug, 1 times / hour
Route: transdermal
Route: multiple
Dose: 150 ug, 1 times / hour
Sources:
unknown, 31
n = 1
Health Status: unknown
Age Group: 31
Sex: M
Population Size: 1
Sources:
Disc. AE: Respiratory arrest...
AEs leading to
discontinuation/dose reduction:
Respiratory arrest (grade 5)
Sources:
225 ug 1 times / hour multiple, transdermal
Overdose
Dose: 225 ug, 1 times / hour
Route: transdermal
Route: multiple
Dose: 225 ug, 1 times / hour
Sources: Page: p.51
unhealthy, 32
n = 1
Health Status: unhealthy
Condition: Knee pain
Age Group: 32
Sex: F
Population Size: 1
Sources: Page: p.51
Disc. AE: Syncope, Acute coronary syndrome...
AEs leading to
discontinuation/dose reduction:
Syncope
Acute coronary syndrome
Sources: Page: p.51
800 ug single, sublingual
Higher than recommended
Dose: 800 ug
Route: sublingual
Route: single
Dose: 800 ug
Sources: Page: p.13, 14
healthy, 33.4
n = 8
Health Status: healthy
Age Group: 33.4
Sex: M+F
Population Size: 8
Sources: Page: p.13, 14
Other AEs: Hypoxia, Nausea...
Other AEs:
Hypoxia (50%)
Nausea (75%)
Sources: Page: p.13, 14
800 ug single, sublingual
Higher than recommended
Dose: 800 ug
Route: sublingual
Route: single
Dose: 800 ug
Sources: Page: p.13, 15
healthy, 33.4
n = 8
Health Status: healthy
Age Group: 33.4
Sex: M+F
Population Size: 8
Sources: Page: p.13, 15
Other AEs: Somnolence...
Other AEs:
Somnolence (87.5%)
Sources: Page: p.13, 15
800 ug single, sublingual
Higher than recommended
Dose: 800 ug
Route: sublingual
Route: single
Dose: 800 ug
Sources: Page: p.13, 16
healthy, 33.4
n = 8
Health Status: healthy
Age Group: 33.4
Sex: M+F
Population Size: 8
Sources: Page: p.13, 16
Other AEs: Vomiting...
Other AEs:
Vomiting (50%)
Sources: Page: p.13, 16
1600 ug 1 times / 15 min multiple, sublingual (max)
Highest studied dose
Dose: 1600 ug, 1 times / 15 min
Route: sublingual
Route: multiple
Dose: 1600 ug, 1 times / 15 min
Sources: Page: p.309
unhealthy, 53±12
n = 65
Health Status: unhealthy
Condition: Pain
Age Group: 53±12
Sex: M+F
Population Size: 65
Sources: Page: p.309
Disc. AE: Somnolence, Dizziness...
AEs leading to
discontinuation/dose reduction:
Somnolence (3%)
Dizziness (3%)
Hallucinations (1.5%)
Dry mouth (1.5%)
Headache (1.5%)
Nausea (1.5%)
Vomiting (1.5%)
Sources: Page: p.309
5 mg single, intravenous
Accidental dose
Dose: 5 mg
Route: intravenous
Route: single
Dose: 5 mg
Sources: Page: p.199
unhealthy, 62
n = 1
Health Status: unhealthy
Condition: Pain
Age Group: 62
Sex: M
Population Size: 1
Sources: Page: p.199
Disc. AE: Confusion, Restlessness...
AEs leading to
discontinuation/dose reduction:
Confusion (acute)
Restlessness (mild)
Visual hallucinations
Sweating
Miosis
Sources: Page: p.199
200 ug 6 times / day multiple, sublingual
Recommended
Dose: 200 ug, 6 times / day
Route: sublingual
Route: multiple
Dose: 200 ug, 6 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.1
Disc. AE: Respiratory depression, Opioid abuse...
AEs leading to
discontinuation/dose reduction:
Respiratory depression (grade 4)
Opioid abuse
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Apnea Disc. AE
6 mg single, transdermal (total)
Overdose
Dose: 6 mg
Route: transdermal
Route: single
Dose: 6 mg
Sources: Page: p.463
healthy, 15
n = 1
Health Status: healthy
Age Group: 15
Sex: F
Population Size: 1
Sources: Page: p.463
Bradypnea Disc. AE
6 mg single, transdermal (total)
Overdose
Dose: 6 mg
Route: transdermal
Route: single
Dose: 6 mg
Sources: Page: p.463
healthy, 15
n = 1
Health Status: healthy
Age Group: 15
Sex: F
Population Size: 1
Sources: Page: p.463
Diaphoresis Disc. AE
6 mg single, transdermal (total)
Overdose
Dose: 6 mg
Route: transdermal
Route: single
Dose: 6 mg
Sources: Page: p.463
healthy, 15
n = 1
Health Status: healthy
Age Group: 15
Sex: F
Population Size: 1
Sources: Page: p.463
Respiratory depression Disc. AE
6 mg single, transdermal (total)
Overdose
Dose: 6 mg
Route: transdermal
Route: single
Dose: 6 mg
Sources: Page: p.463
healthy, 15
n = 1
Health Status: healthy
Age Group: 15
Sex: F
Population Size: 1
Sources: Page: p.463
Tachycardia Disc. AE
6 mg single, transdermal (total)
Overdose
Dose: 6 mg
Route: transdermal
Route: single
Dose: 6 mg
Sources: Page: p.463
healthy, 15
n = 1
Health Status: healthy
Age Group: 15
Sex: F
Population Size: 1
Sources: Page: p.463
Respiratory arrest grade 5
Disc. AE
150 ug 1 times / hour multiple, transdermal
Overdose
Dose: 150 ug, 1 times / hour
Route: transdermal
Route: multiple
Dose: 150 ug, 1 times / hour
Sources:
unknown, 31
n = 1
Health Status: unknown
Age Group: 31
Sex: M
Population Size: 1
Sources:
Acute coronary syndrome Disc. AE
225 ug 1 times / hour multiple, transdermal
Overdose
Dose: 225 ug, 1 times / hour
Route: transdermal
Route: multiple
Dose: 225 ug, 1 times / hour
Sources: Page: p.51
unhealthy, 32
n = 1
Health Status: unhealthy
Condition: Knee pain
Age Group: 32
Sex: F
Population Size: 1
Sources: Page: p.51
Syncope Disc. AE
225 ug 1 times / hour multiple, transdermal
Overdose
Dose: 225 ug, 1 times / hour
Route: transdermal
Route: multiple
Dose: 225 ug, 1 times / hour
Sources: Page: p.51
unhealthy, 32
n = 1
Health Status: unhealthy
Condition: Knee pain
Age Group: 32
Sex: F
Population Size: 1
Sources: Page: p.51
Hypoxia 50%
800 ug single, sublingual
Higher than recommended
Dose: 800 ug
Route: sublingual
Route: single
Dose: 800 ug
Sources: Page: p.13, 14
healthy, 33.4
n = 8
Health Status: healthy
Age Group: 33.4
Sex: M+F
Population Size: 8
Sources: Page: p.13, 14
Nausea 75%
800 ug single, sublingual
Higher than recommended
Dose: 800 ug
Route: sublingual
Route: single
Dose: 800 ug
Sources: Page: p.13, 14
healthy, 33.4
n = 8
Health Status: healthy
Age Group: 33.4
Sex: M+F
Population Size: 8
Sources: Page: p.13, 14
Somnolence 87.5%
800 ug single, sublingual
Higher than recommended
Dose: 800 ug
Route: sublingual
Route: single
Dose: 800 ug
Sources: Page: p.13, 15
healthy, 33.4
n = 8
Health Status: healthy
Age Group: 33.4
Sex: M+F
Population Size: 8
Sources: Page: p.13, 15
Vomiting 50%
800 ug single, sublingual
Higher than recommended
Dose: 800 ug
Route: sublingual
Route: single
Dose: 800 ug
Sources: Page: p.13, 16
healthy, 33.4
n = 8
Health Status: healthy
Age Group: 33.4
Sex: M+F
Population Size: 8
Sources: Page: p.13, 16
Dry mouth 1.5%
Disc. AE
1600 ug 1 times / 15 min multiple, sublingual (max)
Highest studied dose
Dose: 1600 ug, 1 times / 15 min
Route: sublingual
Route: multiple
Dose: 1600 ug, 1 times / 15 min
Sources: Page: p.309
unhealthy, 53±12
n = 65
Health Status: unhealthy
Condition: Pain
Age Group: 53±12
Sex: M+F
Population Size: 65
Sources: Page: p.309
Hallucinations 1.5%
Disc. AE
1600 ug 1 times / 15 min multiple, sublingual (max)
Highest studied dose
Dose: 1600 ug, 1 times / 15 min
Route: sublingual
Route: multiple
Dose: 1600 ug, 1 times / 15 min
Sources: Page: p.309
unhealthy, 53±12
n = 65
Health Status: unhealthy
Condition: Pain
Age Group: 53±12
Sex: M+F
Population Size: 65
Sources: Page: p.309
Headache 1.5%
Disc. AE
1600 ug 1 times / 15 min multiple, sublingual (max)
Highest studied dose
Dose: 1600 ug, 1 times / 15 min
Route: sublingual
Route: multiple
Dose: 1600 ug, 1 times / 15 min
Sources: Page: p.309
unhealthy, 53±12
n = 65
Health Status: unhealthy
Condition: Pain
Age Group: 53±12
Sex: M+F
Population Size: 65
Sources: Page: p.309
Nausea 1.5%
Disc. AE
1600 ug 1 times / 15 min multiple, sublingual (max)
Highest studied dose
Dose: 1600 ug, 1 times / 15 min
Route: sublingual
Route: multiple
Dose: 1600 ug, 1 times / 15 min
Sources: Page: p.309
unhealthy, 53±12
n = 65
Health Status: unhealthy
Condition: Pain
Age Group: 53±12
Sex: M+F
Population Size: 65
Sources: Page: p.309
Vomiting 1.5%
Disc. AE
1600 ug 1 times / 15 min multiple, sublingual (max)
Highest studied dose
Dose: 1600 ug, 1 times / 15 min
Route: sublingual
Route: multiple
Dose: 1600 ug, 1 times / 15 min
Sources: Page: p.309
unhealthy, 53±12
n = 65
Health Status: unhealthy
Condition: Pain
Age Group: 53±12
Sex: M+F
Population Size: 65
Sources: Page: p.309
Dizziness 3%
Disc. AE
1600 ug 1 times / 15 min multiple, sublingual (max)
Highest studied dose
Dose: 1600 ug, 1 times / 15 min
Route: sublingual
Route: multiple
Dose: 1600 ug, 1 times / 15 min
Sources: Page: p.309
unhealthy, 53±12
n = 65
Health Status: unhealthy
Condition: Pain
Age Group: 53±12
Sex: M+F
Population Size: 65
Sources: Page: p.309
Somnolence 3%
Disc. AE
1600 ug 1 times / 15 min multiple, sublingual (max)
Highest studied dose
Dose: 1600 ug, 1 times / 15 min
Route: sublingual
Route: multiple
Dose: 1600 ug, 1 times / 15 min
Sources: Page: p.309
unhealthy, 53±12
n = 65
Health Status: unhealthy
Condition: Pain
Age Group: 53±12
Sex: M+F
Population Size: 65
Sources: Page: p.309
Miosis Disc. AE
5 mg single, intravenous
Accidental dose
Dose: 5 mg
Route: intravenous
Route: single
Dose: 5 mg
Sources: Page: p.199
unhealthy, 62
n = 1
Health Status: unhealthy
Condition: Pain
Age Group: 62
Sex: M
Population Size: 1
Sources: Page: p.199
Sweating Disc. AE
5 mg single, intravenous
Accidental dose
Dose: 5 mg
Route: intravenous
Route: single
Dose: 5 mg
Sources: Page: p.199
unhealthy, 62
n = 1
Health Status: unhealthy
Condition: Pain
Age Group: 62
Sex: M
Population Size: 1
Sources: Page: p.199
Visual hallucinations Disc. AE
5 mg single, intravenous
Accidental dose
Dose: 5 mg
Route: intravenous
Route: single
Dose: 5 mg
Sources: Page: p.199
unhealthy, 62
n = 1
Health Status: unhealthy
Condition: Pain
Age Group: 62
Sex: M
Population Size: 1
Sources: Page: p.199
Confusion acute
Disc. AE
5 mg single, intravenous
Accidental dose
Dose: 5 mg
Route: intravenous
Route: single
Dose: 5 mg
Sources: Page: p.199
unhealthy, 62
n = 1
Health Status: unhealthy
Condition: Pain
Age Group: 62
Sex: M
Population Size: 1
Sources: Page: p.199
Restlessness mild
Disc. AE
5 mg single, intravenous
Accidental dose
Dose: 5 mg
Route: intravenous
Route: single
Dose: 5 mg
Sources: Page: p.199
unhealthy, 62
n = 1
Health Status: unhealthy
Condition: Pain
Age Group: 62
Sex: M
Population Size: 1
Sources: Page: p.199
Opioid abuse Disc. AE
200 ug 6 times / day multiple, sublingual
Recommended
Dose: 200 ug, 6 times / day
Route: sublingual
Route: multiple
Dose: 200 ug, 6 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.1
Respiratory depression grade 4
Disc. AE
200 ug 6 times / day multiple, sublingual
Recommended
Dose: 200 ug, 6 times / day
Route: sublingual
Route: multiple
Dose: 200 ug, 6 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.1
OverviewDrug as perpetrator​

Drug as perpetrator​

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely
likely
major
yes (co-administration study)
Comment: Rate: 61 pmol/min/mg protein; Activity (Fentanyl): 1.03 nmol/min/nmol CYP (Biochem Pharmacol, 53, 1613 (1997)); Coadministartion of Ritonavir (strong CYP3A inhibitor, PO) increased Fentanyl (IV) AUCinf by 2.74-fold.
Page: (Pharm) 17, 28, (PMDA) 17
minor
minor
minor
minor
no
no
no
yes
yes
yes
yes
yes
Tox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
Spasm and operative cholangiography.
1975 Jan
Computerised advice on drug dosage to improve prescribing practice.
2001
A highly automated 96-well solid phase extraction and liquid chromatography/tandem mass spectrometry method for the determination of fentanyl in human plasma.
2001
Abuse of topical analgesic.
2001 Apr
A comparison of ropivacaine with fentanyl to bupivacaine with fentanyl for postoperative patient-controlled epidural analgesia.
2001 Apr
The clinical use of small-dose tetracaine spinal anesthesia for transurethral prostatectomy.
2001 Apr
The effects of opioids on isolated human pregnant uterine muscles.
2001 Apr
Stress response in infants undergoing cardiac surgery: a randomized study of fentanyl bolus, fentanyl infusion, and fentanyl-midazolam infusion.
2001 Apr
Thoracic epidural anesthesia combined with general anesthesia: the preferred anesthetic technique for thoracic surgery.
2001 Apr
[Epileptogenic drugs in anesthesia].
2001 Feb
Comparison of the effects of clonidine and hydroxyzine on haemodynamic and catecholamine reactions to microlaryngoscopy.
2001 Feb
Patient-controlled spinal analgesia for labour and caesarean delivery.
2001 Feb
Anaesthesia for amiodarone-induced thyrotoxicosis: a case review.
2001 Feb
When should diclofenac be given in ambulatory surgery: preoperatively or postoperatively?
2001 Feb
[Anesthesia in a case of Bardet-Biedl syndrome].
2001 Feb
[Prevention of postoperative nausea and vomiting in gynecologic surgery with 3 fixed doses of metoclopramide, droperidol or placebo].
2001 Feb
[Computer simulation and pharmacoeconomics. Computer simulation as an aid for the analysis of operating room efficiency: an example].
2001 Feb
[Anesthetic management for the correction of pectus excavatum using pectus bar under video-assistance].
2001 Feb
[Anesthetic management for left ventricular assist device implantation in patients waiting for heart transplantation].
2001 Feb
[Anesthetic management of two patients with insulinoma using propofol--in association with rapid radioimmunoassay for insulin].
2001 Feb
A randomized prospective comparative study of general versus epidural anesthesia for transcervical hysteroscopic endometrial resection.
2001 Feb
Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain.
2001 Feb
MRCP in the evaluation of pancreaticobiliary disease in children.
2001 Feb
Nociceptin/orphanin FQ exacerbates excitotoxic white-matter lesions in the murine neonatal brain.
2001 Feb
Postoperative sleep disturbance: influences of opioids and pain in humans.
2001 Feb 1
Pre-emptive efficacy of epidural fentanyl in elective abdominal surgery.
2001 Jan
Interscalene brachial plexus anaesthesia with small volumes of ropivacaine 0.75%: effects of the injection technique on the onset time of nerve blockade.
2001 Jan
Comparative analysis of costs of total intravenous anaesthesia with propofol and remifentanil vs. balanced anaesthesia with isoflurane and fentanyl.
2001 Jan
A comparison of remifentanil and fentanyl in patients undergoing carotid endarterectomy.
2001 Jan
Transdermal fentanyl for chronic pain in AIDS: a pilot study.
2001 Jan
Strong opioids for cancer pain.
2001 Jan
High concentration sevoflurane induction of anesthesia accelerates onset of vecuronium neuromuscular blockade.
2001 Jan
[Marked bradycardia during anesthetic induction treated with temporary cardiac pacing in a patient with latent sick sinus syndrome].
2001 Jan
[Anesthesia for a patient with cardiac sarcoidosis].
2001 Jan
[Anesthesia for emergency surgery in a patient with Shy-Drager syndrome].
2001 Jan
[Anesthetic management for mitral valve replacement in a patient with idiopathic hypereosinophilic syndrome].
2001 Jan
[Low concentration/high volume is more effective than high concentration/low volume for postoperative continuous epidural analgesia with the combination of bupivacaine and fentanyl].
2001 Jan
[The effects of intravenous nicardipine on jugular venous oxygen saturation].
2001 Jan
Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.
2001 Jan
Surgery of the canine vagina and vulva.
2001 Mar
Comparison of midazolam with or without fentanyl for conscious sedation and hemodynamics in coronary angiography.
2001 Mar
Cannabinoidergic and opioidergic inhibition of spinal reflexes in the decerebrated, spinalized rabbit.
2001 Mar
A dual epidural catheter technique to provide analgesia following posterior spinal fusion for scoliosis in children and adolescents.
2001 Mar
Anaesthetic technique for transoesophageal echocardiography in children.
2001 Mar
Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).
2001 Mar
Opiate self-administration as a measure of chronic nociceptive pain in arthritic rats.
2001 Mar
The effect of the preemptive use of the NMDA receptor antagonist dextromethorphan on postoperative analgesic requirements.
2001 Mar
The addition of morphine prolongs fentanyl-bupivacaine spinal analgesia for the relief of labor pain.
2001 Mar
Neural circuits regulating pulsatile luteinizing hormone release in the female guinea-pig: opioid, adrenergic and serotonergic interactions.
2001 Mar
Morphine and alternative opioids in cancer pain: the EAPC recommendations.
2001 Mar 2
Patents

Sample Use Guides

Dosage should be individualized. Some of the factors to be considered in determining the dose are age, body weight, physical status, underlying pathological condition, use of other drugs, type of anesthesia to be used and the surgical procedure involved. Dosage should be reduced in elderly or debilitated patients (see PRECAUTIONS). Vital signs should be monitored routinely. I. Premedication — Premedication (to be appropriately modified in the elderly, debilitated and those who have received other depressant drugs) — 50 to 100 mcg (0.05 to 0.1 mg) (1 to 2 mL) may be administered intramuscularly 30 to 60 minutes prior to surgery. II. Adjunct to General Anesthesia — See Dosage Range Chart III. Adjunct to Regional Anesthesia - 50 to 100 mcg (0.05 to 0.1 mg) (1 to 2 mL) may be administered intramuscularly or slowly intravenously, over one to two minutes, when additional analgesia is required. IV. Postoperatively (recovery room) - 50 to 100 mcg (0.05 to 0.1 mg) (1 to 2 mL) may be administered intramuscularly for the control of pain, tachypnea and emergence delirium. The dose may be repeated in one to two hours as needed
Route of Administration: Other
0.5 - 5 ng/ml fentanyl inhibited viability of SW1990 cells in vitro.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:54:47 UTC 2021
Edited
by admin
on Fri Jun 25 20:54:47 UTC 2021
Record UNII
MUN5LYG46H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FENTANYL CITRATE
EMA EPAR   EP   GREEN BOOK   JAN   MART.   MI   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
USAN  
Official Name English
LEPTANAL
Brand Name English
FENTANYL CITRATE [EMA EPAR]
Common Name English
FENTANYL CITRATE CII
USP-RS  
Common Name English
INSTANYL
Brand Name English
KW-2246
Common Name English
SUBLIMAZE
Brand Name English
LAZANDA
Brand Name English
FENTANYL CITRATE [MI]
Common Name English
FENTANYL CITRATE [EP MONOGRAPH]
Common Name English
FENTANYL CITRATE [ORANGE BOOK]
Common Name English
R-4263
Code English
EFFENTORA
Brand Name English
ABSTRAL
Brand Name English
INNOVAR COMPONENT FENTANYL CITRATE
Common Name English
FENTANYL CITRATE [USAN]
Common Name English
FENTANYL CITRATE [WHO-DD]
Common Name English
N-(1-PHENETHYL-4-PIPERIDYL)PROPIONANILIDE CITRATE (1:1)
Systematic Name English
MCN-JR-4263-49
Code English
FENTORA
Brand Name English
FENTANYL CITRATE [USP MONOGRAPH]
Common Name English
PROPANAMIDE, N-PHENYL-N-(1-(2-PHENYLETHYL)-4-PIPERIDINYL)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1)
Systematic Name English
FENTANYL CITRATE CII [USP-RS]
Common Name English
FENTANYL CITRATE [MART.]
Common Name English
FENTANYL CITRATE COMPONENT OF INNOVAR
Common Name English
FENTANYL CITRATE [GREEN BOOK]
Common Name English
ACTIQ
Brand Name English
FENTANYL CITRATE [JAN]
Common Name English
ONSOLIS
Brand Name English
FENTANYL BUCCAL
Brand Name English
FENTANYL CITRATE [VANDF]
Common Name English
Classification Tree Code System Code
DEA NO. 9801
Created by admin on Fri Jun 25 20:54:47 UTC 2021 , Edited by admin on Fri Jun 25 20:54:47 UTC 2021
EMA ASSESSMENT REPORTS INSTANYL (AUTHORIZED: PAIN)
Created by admin on Fri Jun 25 20:54:47 UTC 2021 , Edited by admin on Fri Jun 25 20:54:47 UTC 2021
EMA ASSESSMENT REPORTS EFFENTORA (AUTHORIZED: PAIN)
Created by admin on Fri Jun 25 20:54:47 UTC 2021 , Edited by admin on Fri Jun 25 20:54:47 UTC 2021
NCI_THESAURUS C67413
Created by admin on Fri Jun 25 20:54:47 UTC 2021 , Edited by admin on Fri Jun 25 20:54:47 UTC 2021
CFR 21 CFR 522.800
Created by admin on Fri Jun 25 20:54:47 UTC 2021 , Edited by admin on Fri Jun 25 20:54:47 UTC 2021
NCI_THESAURUS C1506
Created by admin on Fri Jun 25 20:54:47 UTC 2021 , Edited by admin on Fri Jun 25 20:54:47 UTC 2021
Code System Code Type Description
FDA UNII
MUN5LYG46H
Created by admin on Fri Jun 25 20:54:47 UTC 2021 , Edited by admin on Fri Jun 25 20:54:47 UTC 2021
PRIMARY
MERCK INDEX
M5298
Created by admin on Fri Jun 25 20:54:47 UTC 2021 , Edited by admin on Fri Jun 25 20:54:47 UTC 2021
PRIMARY Merck Index
ECHA (EC/EINECS)
213-588-0
Created by admin on Fri Jun 25 20:54:47 UTC 2021 , Edited by admin on Fri Jun 25 20:54:47 UTC 2021
PRIMARY
CAS
990-73-8
Created by admin on Fri Jun 25 20:54:47 UTC 2021 , Edited by admin on Fri Jun 25 20:54:47 UTC 2021
PRIMARY
EPA CompTox
990-73-8
Created by admin on Fri Jun 25 20:54:47 UTC 2021 , Edited by admin on Fri Jun 25 20:54:47 UTC 2021
PRIMARY
NCI_THESAURUS
C47994
Created by admin on Fri Jun 25 20:54:47 UTC 2021 , Edited by admin on Fri Jun 25 20:54:47 UTC 2021
PRIMARY
PUBCHEM
13810
Created by admin on Fri Jun 25 20:54:47 UTC 2021 , Edited by admin on Fri Jun 25 20:54:47 UTC 2021
PRIMARY
DRUG BANK
DBSALT000301
Created by admin on Fri Jun 25 20:54:47 UTC 2021 , Edited by admin on Fri Jun 25 20:54:47 UTC 2021
PRIMARY
RXCUI
142436
Created by admin on Fri Jun 25 20:54:47 UTC 2021 , Edited by admin on Fri Jun 25 20:54:47 UTC 2021
PRIMARY RxNorm
ChEMBL
CHEMBL596
Created by admin on Fri Jun 25 20:54:47 UTC 2021 , Edited by admin on Fri Jun 25 20:54:47 UTC 2021
PRIMARY
USP_CATALOG
1270005
Created by admin on Fri Jun 25 20:54:47 UTC 2021 , Edited by admin on Fri Jun 25 20:54:47 UTC 2021
PRIMARY USP-RS
EVMPD
SUB02129MIG
Created by admin on Fri Jun 25 20:54:47 UTC 2021 , Edited by admin on Fri Jun 25 20:54:47 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY